Table 1.
Baseline a characteristics of patients included in analyses of rapid progression, according to availability of data
| |
|
Patients with eGFR data available |
≥4 years follow-up |
≥3 years follow-up |
||||
|---|---|---|---|---|---|---|---|---|
| Unrestricted f | ≥3 eGFR per year | ≥2 eGFR per year | Unrestricted* | ≥3 eGFR per year | ≥2 eGFR per year | |||
| Eligible patients |
Number (%) |
22603 (100) |
13061 (57.8) |
3655 (16.2) |
8298 (36.7) |
16165 (71.5) |
6375 (28.2) |
12283 (54.3) |
| Average eGFR |
Median (IQR) |
109 (99–123) |
108 (99–122) |
107 (98–121) |
108 (99–121) |
109 (99–122) |
108 (99–122) |
108 (99–122) |
| eGFR >120 ml/min |
Number (%) |
6613 (29.3) |
3616 (27.7) |
943 (26) |
225 (27) |
4562 (28.1) |
1723 (27) |
3412 (28) |
| Gender |
Male |
16438 (72.7) |
9335 (71.5) |
2622 (71.7) |
5999 (72.3) |
11613 (71.8) |
4617 (72.4) |
8906 (72.5) |
| Race |
White |
10573 (46.8) |
6343 (48.6) |
1631 (44.6) |
3835 (46.2) |
7469 (46.2) |
2584 (40.5) |
5454 (44.4) |
| Black |
1806 (8.0) |
1141 (8.7) |
354 (9.7) |
720 (8.7) |
1346 (8.3) |
581 (9.1) |
1023 (8.3) |
|
| Other |
510 (2.3) |
306 (2.3) |
103 (2.8) |
197 (2.4) |
385 (2.4) |
155 (2.4) |
294 (2.4) |
|
| Unknown |
9714 (43.0) |
5271 (40.4) |
1567 (42.9) |
3546 (42.7) |
6965 (43.1) |
3055 (47.9) |
5512 (44.9) |
|
| Age group |
>50 years |
2238 (9.9) |
1280 (9.8) |
410 (11.2) |
868 (10.5) |
1641 (10.2) |
702 (11.0) |
1309 (10.7) |
| Hypertensionb |
Yes |
2519 (11.1) |
1526 (11.7) |
494 (13.5) |
1030 (12.4) |
1865 (11.5) |
784 (12.3) |
1458 (11.9) |
| Diabetesc |
Yes |
659 (2.9) |
428 (3.3) |
145 (4.0) |
290 (3.5) |
517 (3.2) |
237 (3.7) |
413 (3.4) |
| Mode of HIV acquisition |
Homosexual |
10006 (44.3) |
5642 (43.2) |
1611 (44.1) |
3710 (44.7) |
7028 (43.5) |
2876 (45.1) |
5487 (44.7) |
| IDU |
3058 (13.5) |
1783 (13.7) |
450 (12.3) |
1019 (12.3) |
2196 (13.6) |
740 (11.6) |
1540 (12.5) |
|
| Heterosexual |
8095 (35.8) |
4865 (37.3) |
1385 (37.9) |
3081 (37.1) |
5952 (36.8) |
2359 (37.0) |
4499 (36.6) |
|
| Other |
1444 (6.4) |
771 (5.9) |
209 (5.7) |
488 (5.9) |
989 (6.1) |
400 (6.3) |
757 (6.2) |
|
| BMI at study entry (kg/m2) |
<18 |
633 (2.8) |
345 (2.6) |
91 (2.5) |
216 (2.6) |
440 (2.7) |
169 (2.7) |
330 (2.7) |
| ≥18, <26 |
15865 (70.2) |
9310 (71.3) |
2542 (69.6) |
5877 (70.8) |
11473 (71.0) |
4466 (70.1) |
8717 (71.0) |
|
| ≥26, <30 |
3716 (16.4) |
2231 (17.1) |
677 (18.5) |
1466 (17.7) |
2727 (16.9) |
1106 (17.4) |
2088 (17.0) |
|
| ≥30 |
1423 (6.3) |
845 (6.5) |
238 (6.5) |
536 (6.5) |
1037 (6.4) |
398 (6.2) |
774 (6.3) |
|
| Unknown |
966 (4.3) |
330 (2.5) |
107 (2.9) |
203 (2.5) |
488 (3.0) |
236 (3.7) |
374 (3.0) |
|
| Hepatitis Cd positive |
Yes |
2765 (12.2) |
1605 (12.3) |
400 (10.9) |
910 (11.0) |
1958 (12.1) |
653 (10.2) |
1346 (10.6) |
| Hepatitis Be positive |
Yes |
2773 (12.3) |
1551 (12.4) |
450 (12.3) |
1001 (12.1) |
1971 (12.2) |
816 (12.8) |
1501 (12.2) |
| Smoking status |
Current |
9544 (42.2) |
5554 (42.5) |
1467 (40.1) |
3445 (41.5) |
6930 (42.9) |
2571 (40.3) |
5198 (42.3) |
| Previous |
3930 (17.4) |
2426 (18.6) |
681 (18.6) |
1557 (18.8) |
2923 (18.1) |
1193 (18.7) |
2248 (18.3) |
|
| Never |
5824 (25.8) |
3599 (27.6) |
1086 (29.7) |
2332 (28.1) |
4314 (26.7) |
1726 (27.1) |
3299 (26.9) |
|
| Unknown |
3305 (14.6) |
1482 (11.4) |
421 (11.5) |
964 (11.6) |
1998 (12.4) |
885 (13.9) |
1538 (12.5) |
|
| Current CD4 count (cells/mm3) |
<200 |
2823 (12.5) |
1435 (11.0) |
482 (13.2) |
940 (11.3) |
1831 (11.3) |
833 (13.1) |
1424 (11.6) |
| 200-349 |
4912 (21.7) |
2797 (21.4) |
826 (22.6) |
1807 (21.8) |
3427 (21.2) |
1444 (22.7) |
2641 (21.5) |
|
| 350-499 |
5565 (24.6) |
3294 (25.2) |
963 (26.4) |
2109 (25.4) |
4049 (25.1) |
1632 (25.6) |
3078 (25.1) |
|
| ≥500 |
9145 (40.5) |
5492 (42.1) |
1371 (37.5) |
3417 (41.2) |
6779 (41.9) |
2432 (38.2) |
5079 (41.4) |
|
| Missing | 158 (0.7) | 43 (0.3) | 13 (0.4) | 25 (0.3) | 79 (0.5) | 34 (0.5) | 61 (0.5) | |
Abbreviations: eGFR, estimated glomerular filtration rate; IDU, injecting drug user;
aBaseline was defined as the defined as the time, during prospective follow-up, of the first eGFR measurement on or after 1 January 2004.
bHypertension was defined as a blood pressure of ≥150/≥100 mmHg or use of antihypertensive drugs and ace inhibitors.
cDiabetes was defined as receipt of antidiabetic treatment or verification of diabetes in a case report form.
dHepatitis C was defined as detection of antibody to HCV plus detection or unknown presence of HCV RNA.
eHepatitis B was defined as detection of HBV surface antigen, detection of HBV e antigen, or detection of HBV DNA plus antibody to HBV e antigen.
fUnrestricted was defined as no restriction concerning the number of eGFR measurements obtained per year.